← Back to signals
TECH
LONGINSIDER SELLBIO-TECHNE CORP
Funds
3
Score
3.75
vs SPY
-17.3%
Stock return (since Q-end)
-0.9%
SPY return (since Q-end)
+16.3%
Current price
$51.68
News Summary
NegativeBio-Techne missed Q3 earnings and revenue estimates, with organic revenue declining 2% amid continued biotech spending weakness, though management guided to at least mid-single-digit growth for FY2027 as headwinds ease. Multiple analysts have cut price targets significantly (Evercore -20.6%, Stifel -23.1%), citing valuation concerns and macroeconomic risks including potential pharma tariffs and NIH funding uncertainties.
Red flags
- •Q3 adjusted EPS missed consensus by $0.02 (3.6% miss) and revenue missed by ~$12M (~3.7%)
- •Organic revenue declined 2% year-over-year with emerging biotech spending remaining soft
- •Adjusted operating margin compressed 70 basis points YoY due to unfavorable mix and volume deleverage
- •Three major analyst downgrades in May 2026: Evercore (PT $54 vs $68), Deutsche Bank (PT $66 vs $75), Stifel (PT $50 vs $65)
- •Flat guidance for Q4 organic growth with FY2027 dependent on biotech recovery
- •Leadership transition in Diagnostics segment (Dr. McManus departed, Steve Crouse appointed March 1, 2026)
Funds Buying (3)
| Fund | Manager | Shares Held | ∆ Shares | Position Value | QoQ | Status |
|---|---|---|---|---|---|---|
| Maverick Capital | Lee Ainslie | 4.7M | +889K | $247.7B | +23% | Existing |
| Durable Capital Partners | Henry Ellenbogen | 4.5M | +2.4M | $232.9B | +113% | Existing |
| Point72 | Steve Cohen | 295K | +295K | $15.4B | — | NEW |
Shares Held and Position Value reflect total quarter-end holdings. ∆ Shares is the change from the prior quarter.
Insider Activity
| Name | Title | Type | Shares | Price | Value | Filed |
|---|---|---|---|---|---|---|
| Herr Amy E. | — | SELL | 7K | $48.28 | $0.32M | 2026-05-08 |